187 related articles for article (PubMed ID: 32848380)
21. Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat® Inhaler in Patients with Chronic Obstructive Pulmonary Disease.
Aalbers R; Maleki-Yazdi MR; Hamilton A; Waitere-Wijker S; Zhao Y; Amatto VC; Schmidt O; Bjermer L
Adv Ther; 2015 Sep; 32(9):809-22. PubMed ID: 26404912
[TBL] [Abstract][Full Text] [Related]
22. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
23. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
Bai CX; Tang Y; Xin JB; Li YL; Li ZK; Kang J; Huang JA; Xiao W; Wen ZG; Fu XH; He B; Liu CT; Chen P
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):838-844. PubMed ID: 31694094
[No Abstract] [Full Text] [Related]
24. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
25. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
[TBL] [Abstract][Full Text] [Related]
26. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
27. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
28. Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.
Hoogendoorn M; Corro Ramos I; Baldwin M; Luciani L; Fabron C; Detournay B; Rutten-van Mölken MPMH
Int J Chron Obstruct Pulmon Dis; 2019; 14():447-456. PubMed ID: 30863045
[TBL] [Abstract][Full Text] [Related]
29. Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination.
Rogliani P; Ritondo BL; Zerillo B; Cazzola M; Matera MG; Calzetta L
COPD; 2020 Apr; 17(2):215-223. PubMed ID: 32252547
[TBL] [Abstract][Full Text] [Related]
30. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
[TBL] [Abstract][Full Text] [Related]
31. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness
Maltais F; Aumann JL; Kirsten AM; Nadreau É; Macesic H; Jin X; Hamilton A; O'Donnell DE
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30655277
[TBL] [Abstract][Full Text] [Related]
32. Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease.
Takahashi K; Tashiro H; Tajiri R; Takamori A; Uchida M; Kato G; Kurihara Y; Sadamatsu H; Kinoshita T; Yoshida M; Kawaguchi A; Kimura S; Sueoka-Aragane N; Kawayama T;
Int J Chron Obstruct Pulmon Dis; 2021; 16():3297-3307. PubMed ID: 34908832
[TBL] [Abstract][Full Text] [Related]
33. Tiotropium/Olodaterol: A Review in COPD.
Dhillon S
Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
Wang Z; Tadayasu Y; Hu N; Shu S; Hu C; Luo Z
Pulm Pharmacol Ther; 2020 Aug; 63():101944. PubMed ID: 32916296
[TBL] [Abstract][Full Text] [Related]
35. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.
O'Donnell DE; Casaburi R; Frith P; Kirsten A; De Sousa D; Hamilton A; Xue W; Maltais F
Eur Respir J; 2017 Apr; 49(4):. PubMed ID: 28424359
[TBL] [Abstract][Full Text] [Related]
36. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Rogliani P; Ora J; Matera MG
Expert Rev Clin Pharmacol; 2015; 8(5):529-39. PubMed ID: 26294073
[TBL] [Abstract][Full Text] [Related]
37. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
39. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials.
Hohlfeld JM; Furtwaengler A; Könen-Bergmann M; Wallenstein G; Walter B; Bateman ED
Int J Clin Pract; 2015 Jan; 69(1):72-80. PubMed ID: 25496316
[TBL] [Abstract][Full Text] [Related]
40. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).
Buhl R; Maltais F; Abrahams R; Bjermer L; Derom E; Ferguson G; Fležar M; Hébert J; McGarvey L; Pizzichini E; Reid J; Veale A; Grönke L; Hamilton A; Korducki L; Tetzlaff K; Waitere-Wijker S; Watz H; Bateman E
Eur Respir J; 2015 Apr; 45(4):969-79. PubMed ID: 25573406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
